# Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis

> **NCT03900325** · PHASE2 · UNKNOWN · sponsor: **Bird Rock Bio, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Diabetic Gastroparesis

## Interventions

- **DRUG:** Nimacimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03900325
- **Lead sponsor:** Bird Rock Bio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-01
- **Primary completion:** 2020-01
- **Final completion:** 2020-04
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03900325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03900325, "Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy of Nimacimab in Patients With Diabetic Gastroparesis". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03900325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*